第一三共将其全资子公司第一三共Healthcare的全部股份转让给Suntory HD

Tokyo, Japan - (April 16, 2026) – Daiichi Sankyo Company, Limited today announced the appointment ofChief Corporate Affairs Officer under the Global Management Structure effective from April 16, 2026.Tokyo – (April 15, 2026) – DAIICHI SANKYO COMPANY, LIMITED (TSE: 4568; hereinafter “theCompany”) hereby announces that it agreed to transfer all of its shares in DAIICHI SANKYOHEALTHCARE CO., LTD. (hereinafter "DSHC"), a consolidated subsidiary of the Company, to SuntoryHoldings Limited (hereinafter "Suntory HD") (hereinafter "the Stock Transfer"), and today entered into astock transfer agreement (hereinafter "the Stock Transfer Agreement") with Suntory HD. 

The total consideration for the Stock Transfer is expected to be JPY 246.5 billion.The Stock Transfer will be carried out in stages. Specifically, the Company will transfer 30% of theissued shares of DSHC held by the Company to Suntory HD in June 2026, and the transfer is scheduledto be completed by June 2029. 

1. Purpose of the Transfer
   As self-care and self-medication are increasingly promoted in Japan in support of extending healthy lifeexpectancy, DSHC has contributed to the further development of self-medication as a leading companyin the OTC pharmaceutical market, while also expanding into functional skincare, oral care, and foodproducts. Currently, in addition to pharmacies and drugstores, DSHC is strengthening its mail-order saleschannel and expanding its presence overseas.
   
   

   To further grow DSHC’s business, the Company and Suntory HD have determined that it would be optimal to leverage the strengths of Suntory HD, which has established a strong business foundation inthe beverages, food, and health food businesses, and has accordingly entered into this agreement.The Company will concentrate its management resources on its innovative pharmaceutical business,particularly the oncology business, by leveraging its strengths in science and technology, and willcontinue to create and deliver innovative medicines that have the potential to transform the standard ofcare, thereby contributing to the health and enriched lives of people around the world.

2. Overview of subsidiary to be transferred

3. Overview of counterpart to transfer

4. Number of shares transferred, consideration for transfer, and status of shares held before and aftertransfer

(Notes) 

1. A stock split of DSHC shares is scheduled to be executed prior to the execution of the StockTransfer. The number of shares and voting rights above are the numbers after the stock split.4

2. The consideration for transfer above is an estimate as of the current date, and the final price maybe adjusted based on the price adjustment provisions set forth in the Stock Transfer Agreement. 

5. Timeline of transfer

6. Future Outlook 

The impact of the stock transfer on the forecast of the consolidated financial results for the year endingMarch 31, 2027 is still being reviewed. We will inform you as soon as the details are finalized.Additionally, the Company expects to recognize a gain on the stock transfer in the year ending March 31,2028, when its voting rights ratio in DSHC is reduced to 30%.